COVID-19 has emphasized the importance of epidemiologic expertise on many levels, including our work in pharmacoepidemiology. This webpage is dedicated to featuring ISPE members’ work aimed at addressing the pandemic. ISPE members work on every continent and on a broad range of initiatives from determining what drives transmission and prognosis to finding safe and effective treatment and vaccines, from helping to shape policy and guidance to design and govern valid research to integrating relevant topics in educational and outreach activities. Examples of ISPE members’ rapidly evolving work are listed below.
ISPE members are leading activities within OHDSI uses its big data network to generate evidence to support COVID-19 treatment decisions including:
OHDSI posts new outputs on its website at: https://www.ohdsi.org/covid-19-updates
Ensuring Access to Medications in the US During the COVID-19 Pandemic published in JAMA
An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19 published in Ann Intern Med
Searching for an effective Covid-19 treatment: promise and peril published in Stat
ISPE members are evaluating the safety of drugs or drug combinations that are emerging as potential treatments for COVID-19.
ISPE members are working with the Danish Medicines Agency to establish a registry of all Danish COVID-19 patients that is continuously updated and linked to the existing Danish health and administrative registries. This will allow analyses of how drugs, demographic factors and diseases affect the course of COVID-19. More information about the project which is open for collaboration is available here.
ISPE members have worked on a registry aimed at capturing COVID-19 patients’ experiences to inform research and clinical care.
www.helpstopCOVID19.com is a health information exchange that was created to learn about preventative actions, symptoms and what factors increase or decrease people’s chance of getting seriously ill, including evaluation of non-prescription and prescription medicines, vitamins, minerals, herbals, and underlying health conditions. This registry is unique in its focus on non-hospitalized patients and the community reporting of information not routinely included in existing health records. It is currently enrolling participants in the US and UK, and will be rolled out in other countries shortly. As a community, we all need to know about symptoms among those of us who may have been exposed to COVID-19. The developers of the registry are seeking help in promoting awareness about this study. For more information, contact Nancy Dreyer, Matthew Reynolds, or Christina Mack.
UNC Department of Epidemiology and Institute for Global Health and Infectious Diseases, Gillings School of Public Health, University of North Carolina, Chapel Hill
View the webinar
* Note: the case numbers and death count in this webinar are outdated but the content on corona viruses, COVID-19 and how infectious diseases are monitored has not changed.
(Last updated 5/7/2020)